Results 1 to 10 of about 4,395 (86)

[Recent advances in antibody-drug conjugates for metastatic castration-resistant prostate cancer]. [PDF]

open access: yesZhejiang Da Xue Xue Bao Yi Xue Ban
转移性去势抵抗性前列腺癌(mCRPC)患者因肿瘤异质性和耐药性预后不佳,抗体药物偶联物(ADC)治疗mCRPC部分临床试验中已展现出抗肿瘤活性及较好的安全性。在靶向前列腺特异性膜抗原(PSMA)的ADC中,相较于早期ADC如MLN2704、PSMA-ADC、MEDI3726,ARX517安全性更优,前列腺特异性抗原下降更显著。在靶向B7-H3的ADC中,MGC018和DB-1311也展现出抗肿瘤活性。靶向前列腺六跨膜上皮抗原(STEAP)1的DSTP3086S、靶向滋养层细胞表面抗原(TROP ...
Xu J, Ma Y, Hu P, Yao J, Chen H, Ma Q.
europepmc   +2 more sources

Diagnostic value of 18F-PSMA-1007 PET/CT combined with prostate specific antigen derived indicators in gray area prostate cancer. [PDF]

open access: yesZhong Nan Da Xue Xue Bao Yi Xue Ban, 2023
Guo S   +5 more
europepmc   +1 more source

[Clinical Progress and Prospects of mRNA Tumor Drugs]. [PDF]

open access: yesSichuan Da Xue Xue Bao Yi Xue Ban
Chen J   +5 more
europepmc   +1 more source

[A Case of Refractory Pulmonary Enteric Adenocarcinoma with EGFR Sensitive Mutation]. [PDF]

open access: yesZhongguo Fei Ai Za Zhi
Wang X   +7 more
europepmc   +1 more source

[Chinese guidelines for diagnosis and treatment of myelodysplastic neoplasms (2026)]. [PDF]

open access: yesZhonghua Xue Ye Xue Za Zhi
Chinese Society of Hematology   +1 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy